AdaptHealth (AHCO) Stock Forecast, Price Target & Predictions
AHCO Stock Forecast
AdaptHealth stock forecast is as follows: an average price target of $25.40 (represents a 128.83% upside from AHCO’s last price of $11.10) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
AHCO Price Target
The average price target for AdaptHealth (AHCO) is $25.40 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $29.00 to $13.00. This represents a potential 128.83% upside from AHCO's last price of $11.10.
AHCO Analyst Ratings
According to 4 Wall Street analysts, AdaptHealth's rating consensus is 'Buy'. The analyst rating breakdown for AHCO stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
AdaptHealth Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | Kevin Caliendo | UBS | $13.00 | $9.53 | 36.41% | 17.12% |
| Sep 20, 2022 | - | Deutsche Bank | $28.00 | $21.81 | 28.38% | 152.25% |
| Sep 19, 2022 | - | Truist Financial | $28.00 | $20.98 | 33.46% | 152.25% |
| Aug 10, 2022 | - | RBC Capital | $29.00 | $22.24 | 30.40% | 161.26% |
| Aug 10, 2022 | - | Leerink Partners | $29.00 | $22.24 | 30.40% | 161.26% |
| Jul 26, 2022 | David MacDonald | Truist Financial | $24.00 | $21.00 | 14.29% | 116.22% |
The latest AdaptHealth stock forecast, released on Aug 08, 2024 by Kevin Caliendo from UBS, set a price target of $13.00, which represents a 36.41% increase from the stock price at the time of the forecast ($9.53), and a 17.12% increase from AHCO last price ($11.10).
AdaptHealth Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 1 |
| Avg Price Target | $13.00 | $13.00 | $13.00 |
| Last Closing Price | $11.10 | $11.10 | $11.10 |
| Upside/Downside | 17.12% | 17.12% | 17.12% |
In the current month, the average price target of AdaptHealth stock is $13.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 17.12% increase as opposed to AdaptHealth's last price of $11.10. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 08, 2024 | UBS | Buy | Buy | Hold |
| May 15, 2024 | UBS | Buy | Buy | Hold |
| Mar 04, 2024 | UBS | Buy | Buy | Hold |
| Mar 04, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Sep 20, 2022 | Deutsche Bank | Buy | Buy | Hold |
| Sep 19, 2022 | Susquehanna | Buy | Buy | Hold |
| Aug 10, 2022 | RBC Capital | Outperform | Outperform | Hold |
| Aug 10, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Feb 18, 2022 | SVB Leerink | Outperform | Outperform | Hold |
AdaptHealth's last stock rating was published by UBS on Aug 08, 2024. The company gave AHCO a "Buy" rating, the same as its previous rate.
AdaptHealth Financial Forecast
AdaptHealth Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $858.23M | $804.03M | $793.29M | $744.63M | $780.28M | $557.65M | - | $706.20M | $702.11M | $653.29M | $617.02M | $482.12M | $348.43M | $284.40M | $232.12M | $191.44M | $529.64M |
| Avg Forecast | $984.24M | $901.93M | $903.35M | $883.94M | $918.30M | $851.51M | $849.21M | $833.51M | $867.83M | $809.31M | $802.62M | $769.87M | $825.45M | $796.60M | $765.17M | $756.47M | $788.13M | $737.93M | $724.22M | $651.42M | $689.92M | $638.74M | $574.03M | $486.34M | $323.10M | $265.25M | $196.28M | $177.41M | $142.25M |
| High Forecast | $995.73M | $912.47M | $913.89M | $894.26M | $929.02M | $861.45M | $859.13M | $843.24M | $877.97M | $829.53M | $811.99M | $778.86M | $830.51M | $805.90M | $774.10M | $765.30M | $797.33M | $746.55M | $724.22M | $651.42M | $689.92M | $638.74M | $574.03M | $486.34M | $323.10M | $265.25M | $196.28M | $177.41M | $142.25M |
| Low Forecast | $981.29M | $899.23M | $900.64M | $881.29M | $915.55M | $848.96M | $846.67M | $831.01M | $865.24M | $797.56M | $800.22M | $767.57M | $817.52M | $794.21M | $762.88M | $754.20M | $785.77M | $735.72M | $724.22M | $651.42M | $689.92M | $638.74M | $574.03M | $486.34M | $323.10M | $265.25M | $196.28M | $177.41M | $142.25M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 1.01% | 1.04% | 0.98% | 0.99% | 0.76% | - | 1.08% | 1.02% | 1.02% | 1.07% | 0.99% | 1.08% | 1.07% | 1.18% | 1.08% | 3.72% |
AdaptHealth's average Quarter revenue forecast for Mar 24 based on 4 analysts is $769.87M, with a low forecast of $767.57M, and a high forecast of $778.86M. AHCO's average Quarter revenue forecast represents a -10.30% decrease compared to the company's last Quarter revenue of $858.23M (Dec 23).
AdaptHealth EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-227.64M | $-441.83M | $67.48M | $118.81M | $50.44M | $145.02M | - | $122.92M | $135.80M | $164.32M | $178.38M | $63.73M | $-41.92M | $32.03M | $31.71M | $25.63M | $-6.43M |
| Avg Forecast | $126.61M | $116.03M | $116.21M | $113.71M | $118.13M | $109.54M | $109.24M | $107.22M | $111.64M | $104.11M | $103.25M | $252.68M | $106.19M | $102.48M | $98.43M | $229.70M | $101.39M | $229.66M | $93.17M | $208.82M | $183.33M | $208.78M | $381.97M | $124.69M | $41.56M | $66.52M | $45.06M | $46.85M | $-19.86M |
| High Forecast | $128.09M | $117.38M | $117.57M | $115.04M | $119.51M | $110.82M | $110.52M | $108.48M | $112.94M | $106.71M | $104.46M | $303.21M | $106.84M | $103.67M | $99.58M | $275.65M | $102.57M | $275.59M | $93.17M | $250.59M | $220.00M | $250.54M | $458.37M | $149.63M | $41.56M | $79.82M | $54.07M | $56.22M | $-15.88M |
| Low Forecast | $126.24M | $115.68M | $115.86M | $113.37M | $117.78M | $109.21M | $108.92M | $106.90M | $111.31M | $102.60M | $102.94M | $202.14M | $105.17M | $102.17M | $98.14M | $183.76M | $101.08M | $183.73M | $93.17M | $167.06M | $146.67M | $167.03M | $305.58M | $99.75M | $41.56M | $53.22M | $36.05M | $37.48M | $-23.83M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -2.14% | -4.31% | 0.69% | 0.52% | 0.50% | 0.63% | - | 0.59% | 0.74% | 0.79% | 0.47% | 0.51% | -1.01% | 0.48% | 0.70% | 0.55% | 0.32% |
5 analysts predict AHCO's average Quarter EBITDA for Sep 23 to be $102.48M, with a high of $103.67M and a low of $102.17M. This is 51.87% upper than AdaptHealth's previous annual EBITDA (Jun 23) of $67.48M.
AdaptHealth Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-254.50M | $-454.08M | $13.98M | $15.71M | $-1.57M | $16.12M | - | $41.75M | $23.47M | $58.09M | $79.11M | $-3.97M | $-65.87M | $-2.49M | $4.03M | $-158.16K | $-15.00M |
| Avg Forecast | $74.03M | $42.57M | $45.89M | $37.08M | $53.24M | $33.14M | $33.59M | $24.87M | $48.46M | $25.94M | $26.14M | $70.72M | $26.19M | $26.88M | $17.91M | $64.30M | $42.16M | $81.19M | $39.06M | $58.45M | $30.97M | $73.81M | $169.40M | $-7.76M | $26.02M | $-5.17M | $5.73M | $-289.16K | $-46.28M |
| High Forecast | $75.15M | $43.21M | $46.58M | $37.64M | $54.05M | $33.65M | $34.10M | $25.24M | $49.19M | $31.12M | $26.54M | $84.87M | $30.11M | $27.29M | $18.18M | $77.15M | $42.80M | $97.43M | $39.06M | $70.14M | $37.17M | $88.57M | $203.28M | $-6.21M | $26.02M | $-4.14M | $6.88M | $-231.32K | $-37.03M |
| Low Forecast | $73.74M | $42.40M | $45.71M | $36.93M | $53.03M | $33.01M | $33.45M | $24.77M | $48.27M | $22.05M | $26.04M | $56.58M | $18.33M | $26.77M | $17.84M | $51.44M | $41.99M | $64.95M | $39.06M | $46.76M | $24.78M | $59.05M | $135.52M | $-9.31M | $26.02M | $-6.20M | $4.58M | $-346.99K | $-55.54M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -9.72% | -16.89% | 0.78% | 0.24% | -0.04% | 0.20% | - | 0.71% | 0.76% | 0.79% | 0.47% | 0.51% | -2.53% | 0.48% | 0.70% | 0.55% | 0.32% |
AdaptHealth's average Quarter net income forecast for Sep 23 is $26.88M, with a range of $26.77M to $27.29M. AHCO's average Quarter net income forecast represents a 92.30% increase compared to the company's last Quarter net income of $13.98M (Jun 23).
AdaptHealth SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $47.29M | $45.20M | $50.08M | $47.52M | $37.45M | $40.68M | - | $41.44M | $34.92M | $33.01M | $42.95M | $56.63M | $31.60M | $26.31M | $17.09M | $14.35M | $53.21M |
| Avg Forecast | $68.51M | $62.78M | $62.88M | $61.53M | $63.92M | $59.27M | $59.11M | $58.02M | $60.41M | $56.33M | $55.87M | $70.21M | $57.46M | $55.45M | $53.26M | $63.82M | $54.86M | $46.13M | $50.41M | $58.02M | $47.14M | $41.94M | $91.96M | $110.80M | $22.49M | $54.64M | $24.29M | $26.23M | $9.90M |
| High Forecast | $69.31M | $63.51M | $63.61M | $62.25M | $64.67M | $59.96M | $59.80M | $58.69M | $61.11M | $57.74M | $56.52M | $84.25M | $57.81M | $56.10M | $53.88M | $76.59M | $55.50M | $55.36M | $50.41M | $69.63M | $56.57M | $50.32M | $110.36M | $132.96M | $22.49M | $65.56M | $29.15M | $31.48M | $9.90M |
| Low Forecast | $68.30M | $62.59M | $62.69M | $61.34M | $63.73M | $59.09M | $58.93M | $57.84M | $60.23M | $55.52M | $55.70M | $56.16M | $56.90M | $55.28M | $53.10M | $51.06M | $54.69M | $36.90M | $50.41M | $46.42M | $37.71M | $33.55M | $73.57M | $88.64M | $22.49M | $43.71M | $19.43M | $20.98M | $9.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.82% | 0.82% | 0.94% | 0.74% | 0.68% | 0.88% | - | 0.71% | 0.74% | 0.79% | 0.47% | 0.51% | 1.41% | 0.48% | 0.70% | 0.55% | 5.37% |
AdaptHealth's average Quarter SG&A projection for Mar 24 is $70.21M, based on 4 Wall Street analysts, with a range of $56.16M to $84.25M. The forecast indicates a 48.45% rise compared to AHCO last annual SG&A of $47.29M (Dec 23).
AdaptHealth EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-1.91 | $-3.37 | $0.10 | $0.11 | $-0.01 | $0.11 | - | $0.29 | $0.18 | $0.40 | $0.56 | $-0.04 | $-0.47 | $-0.04 | $0.09 | $-0.00 | $-0.10 |
| Avg Forecast | $0.54 | $0.31 | $0.34 | $0.27 | $0.39 | $0.24 | $0.25 | $0.18 | $0.36 | $0.19 | $0.19 | $0.06 | $0.19 | $0.20 | $0.13 | $0.10 | $0.31 | $0.31 | $0.29 | $0.21 | $0.38 | $0.35 | $0.25 | $0.25 | $0.20 | $0.10 | $0.11 | $0.12 | $0.06 |
| High Forecast | $0.55 | $0.32 | $0.34 | $0.28 | $0.40 | $0.25 | $0.25 | $0.19 | $0.36 | $0.23 | $0.20 | $0.06 | $0.22 | $0.20 | $0.13 | $0.10 | $0.31 | $0.31 | $0.29 | $0.21 | $0.38 | $0.35 | $0.25 | $0.25 | $0.20 | $0.10 | $0.11 | $0.12 | $0.06 |
| Low Forecast | $0.54 | $0.31 | $0.34 | $0.27 | $0.39 | $0.24 | $0.25 | $0.18 | $0.35 | $0.16 | $0.19 | $0.06 | $0.13 | $0.20 | $0.13 | $0.10 | $0.31 | $0.31 | $0.29 | $0.21 | $0.38 | $0.35 | $0.25 | $0.25 | $0.20 | $0.10 | $0.11 | $0.12 | $0.06 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -9.92% | -17.06% | 0.76% | 1.13% | -0.04% | 0.36% | - | 1.41% | 0.48% | 1.16% | 2.23% | -0.16% | -2.40% | -0.39% | 0.79% | -0.03% | -1.55% |
According to 5 Wall Street analysts, AdaptHealth's projected average Quarter EPS for Sep 23 is $0.20, with a low estimate of $0.20 and a high estimate of $0.20. This represents a 97.59% increase compared to AHCO previous annual EPS of $0.10 (Jun 23).
AdaptHealth Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| APYX | Apyx Medical | $1.30 | $8.50 | 553.85% | Buy |
| AHCO | AdaptHealth | $11.10 | $25.40 | 128.83% | Buy |
| OFIX | Orthofix Medical | $16.24 | $31.00 | 90.89% | - |
| NPCE | NeuroPace | $7.20 | $12.88 | 78.89% | Buy |
| LUNG | Pulmonx | $7.31 | $12.25 | 67.58% | Buy |
| SGHT | Sight Sciences | $6.35 | $10.33 | 62.68% | Hold |
| FNA | Paragon 28 | $7.30 | $11.50 | 57.53% | Buy |
| LIVN | LivaNova | $47.06 | $71.25 | 51.40% | Buy |
| KIDS | OrthoPediatrics | $30.66 | $44.40 | 44.81% | Buy |
| AORT | Artivion | $25.11 | $30.00 | 19.47% | Buy |
| AVNS | Avanos Medical | $23.72 | $27.00 | 13.83% | Hold |
| SRDX | Surmodics | $38.83 | $39.50 | 1.73% | Buy |
| ITGR | Integer | $129.00 | $131.00 | 1.55% | Buy |
AHCO Forecast FAQ
Is AdaptHealth a good buy?
Yes, according to 4 Wall Street analysts, AdaptHealth (AHCO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of AHCO's total ratings.
What is AHCO's price target?
AdaptHealth (AHCO) average price target is $25.4 with a range of $13 to $29, implying a 128.83% from its last price of $11.1. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will AdaptHealth stock go up soon?
According to Wall Street analysts' prediction for AHCO stock, the company can go up by 128.83% (from the last price of $11.1 to the average price target of $25.4), up by 161.26% based on the highest stock price target, and up by 17.12% based on the lowest stock price target.
Can AdaptHealth stock reach $20?
AHCO's average twelve months analyst stock price target of $25.4 supports the claim that AdaptHealth can reach $20 in the near future.
What is AdaptHealth's current price target trend?
1 Wall Street analyst forecast a $13 price target for AdaptHealth (AHCO) this month, up 17.12% from its last price of $11.1. Compared to the last 3 and 12 months, the average price target increased by 17.12% and increased by 17.12%, respectively.
What are AdaptHealth's analysts' financial forecasts?
AdaptHealth's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.45B (high $3.49B, low $3.44B), average EBITDA is $444.14M (high $449.33M, low $442.81M), average net income is $144.84M (high $147.04M, low $144.27M), average SG&A $240.32M (high $243.12M, low $239.6M), and average EPS is $1.06 (high $1.08, low $1.06). AHCO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.67B (high $3.72B, low $3.66B), average EBITDA is $472.56M (high $478.08M, low $471.15M), average net income is $199.56M (high $202.59M, low $198.78M), average SG&A $255.7M (high $258.68M, low $254.93M), and average EPS is $1.47 (high $1.49, low $1.46).
Did the AHCO's actual financial results beat the analysts' financial forecasts?
Based on AdaptHealth's last annual report (Dec 2023), the company's revenue was $3.2B, beating the average analysts forecast of $3.14B by 1.80%. Apple's EBITDA was $-541M, missing the average prediction of $536.8M by -200.69%. The company's net income was $-679M, missing the average estimation of $135.26M by -601.90%. Apple's SG&A was $190.09M, missing the average forecast of $229.99M by -17.35%. Lastly, the company's EPS was $-5.05, missing the average prediction of $0.619 by -916.29%. In terms of the last quarterly report (Dec 2023), AdaptHealth's revenue was $858.23M, beating the average analysts' forecast of $825.45M by 3.97%. The company's EBITDA was $-228M, missing the average prediction of $106.19M by -314.37%. AdaptHealth's net income was $-255M, missing the average estimation of $26.19M by -1071.92%. The company's SG&A was $47.29M, missing the average forecast of $57.46M by -17.69%. Lastly, the company's EPS was $-1.91, missing the average prediction of $0.193 by -1092.21%